Recent advances in the treatment of testicular cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 1, 2005, Pages 123-138

  Huddart, Robert A ^a   Birtle, Alison J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Combination cytotoxic chemotherapy; Prognosis; State I disease; Testicular cancer

Indexed keywords

ALKYLATING AGENT; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYDROCORTISONE; IFOSFAMIDE; IRINOTECAN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MAGNESIUM; METHOTREXATE; OXALIPLATIN; PACLITAXEL; POTASSIUM; PYRAZOLACRIDINE; STEROID; TEMOZOLOMIDE; TOPETECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANGINA PECTORIS; AREA UNDER THE CURVE; AVASCULAR NECROSIS; AZOOSPERMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SUBSTITUTION; ENDOTHELIUM LESION; FATIGUE; HEART INFARCTION; HIGH RISK PATIENT; HIP DISEASE; HUMAN; INFERTILITY; KIDNEY FAILURE; KIDNEY INJURY; LEUKEMIA; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NAIL COLOR DEFECT; NAUSEA AND VOMITING; NERVE INJURY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SECOND CANCER; SEMINOMA; SENSORY NERVE; SEPSIS; SIDE EFFECT; SKIN DEFECT; SUBSTITUTION THERAPY; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ETOPOSIDE; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 14244254698     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.1.123     Document Type: Review

References (115)

1. Cancer Research Campaign. Testicular Cancer - UK. Factsheet 16(1), 1-6 (1998).
2. International Germ Cell Consensus Classification. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15(2), 594-603 (1997).
3. Peckham MJ. Investigations and staging-general aspects and staging classification. In: The Management of Testicular Tumors. Edward Arnold, London, UK, 89-101 (1971).
4. Huddart R, Norman A, Coward D et al. The health of long-term survivors of testicular cancer. Proc. Am. Soc. Clin. Oncol. 331a (2000) (Abstract 1301).
5. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumors. Ann. Oncol. 14(1), 91-96 (2003).
6. Cook A, Dzik-Jurasz A, Padhani A, Norman A, Huddart R. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumors. Br. J. Cancer 85(11), 1624-1626 (2001).
7. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol. 15(1), 239-45 (1997).
8. De Santis M, Albrecht W, Hold W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int. J. Cancer 83(6), 864-865 (1999).
9. Travis L, Curtis R, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89(19), 1429-1439 (1997).
10. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumors. Br. J. Cancer 90(3), 607-12 (2004).
11. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22(4), 640-647 (2004).
12. Huddart R, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular ca.ncer. J. Clin. Oncol. 21(18), 1513-1523 (2003).
13. Meinardi M, Gietema J, van der Graaf W et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18(8), 1725-1732 (2000).
14. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk Stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol. 14(4), 1106-1113 (1996).
15. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance fir Stage I taticular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol. 10(11), 1762-68 (1992).
16. Sweeney C, Hermans B, Heilman D, Foster R, Donohue J, Einhorn L. Results and outcome of retroperitoneal lymph node node dissection for clinical Stage I embryonal carcinoma-predominant testis cancer. J. Clin. Oncol. 18(2), 358-362 (2000).
17. Moynihan CM. Testicular cancer: the psychosocial problems of patients and their relatives. Cancer Surveys 6(3), 477-510 (1987).
18. Heidenreich A, Sesterhenn I, Moul J. Prognostic risk factors in low Stage testicular germ cell tumors. Cancer 79(9), 1641-1645 (1997).
19. Vergouwe Y, Steyerberg E, Eijkemans M, Albers P, Habbema J. Predictors of occult metastasis in clinical Stage I nonseminoma: a systematic review. J. Clin. Oncol. 21(22), 4092-4099 (2003).
20. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with Stage I non-seminomatous germ cell tumors. Eur. J. Nucl. Med. Mol. Imaging 30(3), 396-402 (2003).
21. Hart, Wall. Radiation Exposure of the UK Population from Medical and Dental X-ray Examination. National Radiological Protection Board, Oxfordshire, UK, NRPB-W4 (2002).
22. Harvey M, Geldart T, Duell R, Mead G, Tung K. Routine computerised. tomographic scans of the thorax in surveillance of Stage I testicular non-seminomatous germ-cell cancer - a necessary risk? Ann. Oncol. 13, 237-242 (2002).
23. Anzai Y, Piccoli CW, Outwater EK et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology 228(3), 777-788 (2003).
24. Clinical Oncology Information Network (CION) Guidelines. Guidelines on the management of adult testicular cancer. J. Clin. Oncol. 12(5), S173-S210 (2000).
25. Fosså SD, Horwich A, Russell J et al. Optimal planning target volume for Stage I testicular seminoma: a Medical Research Council randomized trial. J. Clin. Oncol. 17(4), 1146-1154 (1999).
26. Peckham MJ, Barrett A, Liew K et al. The treatment of metastatic germ-cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br. J. Cancer 47(5), 613-619 (1983).
27. Jones W, Fossa S, Meas G et al. A randomized trial of two radiotherapy schedules in the adjuvant of Stage I seminoma (MRC TE18) - preliminary report. In: Germ Cell Tumors V. Springer, Berlin, Germany, 235-236 (2002).
28. Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue JP. Patterns of relapse following radiotherapy for Stage I seminoma of the testis: implications for follow-up. Clin. Oncol. (R. Coll. Radiol.) 13(4), 296-300 (2001).
29. Horwich A. Surveillance for Stage I seminoma ofthe testis. In: Testicular Cancer Clinical Investigation and Management. Chapman and Hall Medical, London, UK, Chapter 7, 109-116 (1991).
30. Bayley A, Warde P, Milosevic M, Goospodarowicz M. Surveillance for Stage I testicular seminoma. Urol. Oncol. 6(4), 139-143 (2001).
31. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in Stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20(22), 4448-4452 (2002).
32. Oliver RTD, Edmonds PM, Ong JYH et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for Stage I seminoma: should it be tested in a randomized trial against radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 29(1), 3-8 (1994).
33. Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical Stage I seminoma: is a single course of carboplatin sufficient? Urology 55(1), 102-106 (2000).
34. Oliver R, Mason M, Von der Masse H et al. A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of Stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Proc. Am. Soc. Clin. Oncol. 22 (2004) (Abstract 4517).
35. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors: with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316(23), 1435-1440 (1987).
36. Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PER) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann. Oncol. 7(10), 1015-1021 (1996).
37. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplahtin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J. Clin. Oncol. 15(5), 1844-1852 (1997).
38. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J. Clin. Oncol. 11(4), 598-606 (1993).
39. Simpson A, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-1995: a review of patients with germ cell tumors. Br. J. Cancer 78(8), 1061-1066 (1998).
40. Levi J, Raghaven D, Harvey V et al. The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. J. Clin. Oncol. 11(7), 1300-1305 (1993).
41. Bosl GJ, Geller N, Bajorin D et al. A randomized trial of etoposide + cisplatin versus VAB-6 (vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin) in patients with good prognosis germ cell tumor. J. Clin. Oncol. 6(8), 1231-1238 (1988).
42. de Wit R, Storer G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: a randomized study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group. J. Clin. Oncol. 15(5), 1837-1843 (1997).
43. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Co-operative Oncology Group Trial. J. Clin. Oncol. 13(2), 470-476 (1995).
44. Boublikova L, Oliver R, Shamash J et al. Bleomycin in combination chemotherapy of testicular or extragonadal germ cell tumors: a review of published trials. In: Germ Cell Tumors V. Harnden P, Joffe K, Jones W (Eds), Springer-Verlag, London, UK, 244-246 (2002).
45. de Wit R, Roberts J, Wilkinson P, de Mulder P et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin. Oncol. 19(6), 1629-1640 (2001).
46. Saxman B, Finch D, Gonin R, Eihnorn LH. Long-term follow-up of a Phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ cell tumors: the Indiana University Experience. J. Clin. Oncol. 16, 702-706 (1998).
47. Sonneveld D, Hoekstra H, van de Graaf W et al. Improved long-term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91(7), 1304-1315 (2001).
48. Aass N, Klepp O, Cavallin Stahl E et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J. Clin. Oncol. 9(5), 818-826 (1991).
49. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 314(8851), 999-1002 (1993).
50. Collette L, Sylvester R, Staining S et al. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. J. Natl Cancer Inst. 91(10), 839-846 (1999).
51. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J. Clin. Oncol. 16(2), 692-701 (1998).
52. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Co-operative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J. Clin. Oncol. 16(4), 1287-1293 (1998).
53. Bower M, Newlands E, Holden L, Rustin G, Regent R. Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy. Ann. Oncol. 8(5), 477-483 (1997).
54. Bhala N, Coleman JM, Radstone CR et al. The management and survival of patients with advanced germ-cell tumors: improving outcome in intermediate and poor prognosis patients. Clin. Oncol. (R. Coll. Radiol.) 16(1), 40-7 (2004).
55. Droz JP, Culine S, Bouzy J et al. Preliminary results of a randomized trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin/vinblastin, bleomycin (CISCA/VB) for patients (pts) with intermediate- and poor-risk metastatic non-seminomatous germ-cell tumors (NSGCT). Proc. Am. Soc. Clin. Oncol. 173a (2001) (Abstract 690).
56. Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur. Urol. 23(1), 213-218 (1993).
57. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended Phase I/II study of the German Testicular Cancer Study Group. J Clin. Oncol. 21(22), 4083-4091 (2003).
58. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J. Clin. Oncol. 17(11), 3450-3456 (1999).
59. Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. Semin. Oncol. 25(2 Suppl. 4), 24-32 (1998).
60. Price P, Hogan SJ, Horwich A. The growth rate of metastatic non-seminomatous germ cell testicular tumors measured by marker production doubling time-I. Theoretical basis and practical application. Eur. J. Cancer 26(4), 450-453 (1990).
61. Davis A, Tannock I. Repopulation of tumor cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 1, 86-93 (2000).
62. Dearnaley DP. Intensive induction chemotherapy for poor risk tumors. In: Testicular Cancer - Investigation and Management. 2nd edition. Horwich A (Ed.), Chapman and Hall Medical, London, 271-285 (1996).
63. Wettlaufer JN, Feiner AS, Robinson WA. Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer 53, 203-209 (1984).
64. Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 36, 318-326 (1975).
65. Gerson R, Tellez BE, Lazaro LM et al. Low toxicity with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer. Am J. Clin. Oncol. 16(4), 323-326 (1993).
66. Christian JA, Huddart RA, Norman A et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J. Clin. Oncol. 21(5), 871-877 (2003).
67. Fizazi K, Prow DM, Do KA et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors. Br. J. Cancer 86(10), 1555-1560 (2002).
68. van Dijk MR, Steyerberg EW, Stenning SP, Habbema JD. Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: a validation study. Ann. Oncol. 15(9), 1400-1405 (2004).
69. Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markets predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J. Clin. Oncol. 22(19), 3868-3876 (2004).
70. Stevens MJ, Norman AR, Dearnaley DP, Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J. Clin. Oncol. 13(1), 87-92 (1995).
71. de Wit R, Sylvester R, Tsitsa C et al. Tumor marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br. J. Cancer 75(3), 432-435 (1997).
72. Donohue J, Leviovitch I, Foster R, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin. Urol. Oncol. 16(2), 65-71 (1998).
73. Gelderman W, Oosterhuis J, Koops H, Oldhoff J, Sleijfer D. Late recurrence of mature teratoma in nonseminomatous testicular tumor after PVB chemotherapy and surgery. Urology 33, 10-14 (1989).
74. Hendry W. Decision making in abdominal surgery following chemotherapy for testicular cancer. Eur. J. Cancer 31A(5), 649-650 (1995).
75. Logothetis CJ, Samuels ML, Trindale A, Johnson DE. The growing teratoma syndrome. Cancer 50, 1629-1635 (1982).
76. Gerl A, Clemm. C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann. Oncol. 8, 41-47 (1997).
77. Shahidi M, Norman A, Nicholls J, Dearnaley D, Horwich A, Huddart R. Late recurrence in 1263 men with testicular germ cell tumors: multivariate analysis of risk factors and implications for management. Cancer 95(3), 520-530 (2002).
78. Jones W, Stenning S, Read G et al. Long-term follow-up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16): a preliminary report. In: Germ Cell Tumors IV. Jones W, Appleyard I, Harnden P, Joffe J (Eds), John Libbey & Company Ltd, London, UK, 269-275 (1998).
79. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testiculas cancer and minimal residual tumor masses. J. Clin. Oncol. 21(17), 3310-3317 (2003).
80. Hendry W, Norman A, Dearnaley D et al. Metastatic nonseminomatous germ cell tumors of the testis - results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94(6), 1668-1676 (2002).
81. Steyerberg EW, Gerl A, Fossa SD et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol. 16(1), 269-274 (1998).
82. Vergouwe Y, Steyerberg E, Foster R, Habbema D, Donohue J. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J. Urol. 165(1), 84-88 (2001).
83. Steyerberg EW, Donohue JP, Gerl A et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J. Urol. 158(2), 474-478 (1997).
84. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy. J. Clin. Oncol. 19(10), 2647-2657 (2001 ).
85. Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J. Clin. Oncol. 14(2), 454-460 (1996).
86. Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role. MRC Testicular Tumor Working Party. Eur. J. Cancer 33(6), 829-835 (1997).
87. 18 fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 22(6), 1034-1039 (2004).
88. Fosså S, Stenning S, Gerl A et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumors. Br. J. Cancer 80(9), 1392-1399 (1999).
89. McCaffrey J, Mazumdar M, Bajorin D, Bosl G, Vlamis V, Motzer R. Ifosfamide and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol. 15(7), 2559-2563 (1997).
90. Loehrer P, Gonin R, Nichols C, Weathers T, Einhorn L. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol. 16(7), 2500-2504 (1998 ).
91. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol. 14(10), 2638-2645 (1996).
92. Horwich A. Salvage therapy of germ cell tumors. Br. J. Cancer 71(5), 901-903 (1995).
93. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol. 13(4), 599-605 (2002).
94. Rosti G, Pico J-L, Wandt H et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc. Am. Soc. Clin. Oncol. 180a (2002) (Abstract 716).
95. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients witdh previously treated germ cell tumors. J. Clin. Oncol. 12(11), 2277-2283 (1994 ).
96. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann. Oncol. 7(1), 31-34 (1996).
97. Bokemeyer C, Gerl A. Schoffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J. Clin. Oncol. 17(2), 512-516 (1999).
98. Einhorn L, Stender M, Williams S. Phase II trial of gemcitabine in refractory germ cell tumors. J. Clin. Oncol. 17(2), 509-511 (1999).
99. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 20(8), 2031-2037 (2002).
100. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol. 19(1), 81-88 (2001).
101. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol. 18(6), 1173-1180 (2000).
102. Fosså SD, Kaye SB, Mead GM et al. An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing treatment with/without filgrastim (G-CSF). Proc. Am. Soc. Clin. Oncol. 14, 245 (1995).
103. Bokemeyer C, Schmoll H-J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol. 11(9), 1703-1709 (1993).
104. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J. Clin. Oncol. 11(3), 415-424 (1993).
105. Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97(8), 1869-1875 (2003).
106. Germa-Lluch JR, Garcia del Muro X, Tabernero JM et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann. Oncol. 10(3), 289-293 (1999).
107. Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs 13(2), 163-165 (1995).
108. Kondagunta GV, Sheinfeld J, Mazumdar M et al. Relapse-free and overall survival in patients with pathologic Stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J. Clin. Oncol. 22(3), 464-467 (2004).
109. Kollmannsberger C, Gerl A, Schleucher N et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 11(7), 535-539 (2000).
110. Vuky J, McCaffrey J, Ginsberg M et al. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs 18(3), 265-267 (2000).
111. Sandler A, Fox S, Meyers T et al. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a Phase I trial. Am. J. Clin. Oncol. 21(2), 180-184 (1998).
112. Motzer RJ, Sheinfeld J, Mazumdar M J et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 18(12), 2413-2418 (2000).
113. Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J. Clin. Oncol. 20(7), 1859-1863 (2002).
114. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a Phase II study. Eur. Urol. 46(2), 216-221 (2004).
115. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer. a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 22(1), 108-114 (2004).